Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial

Following the tremendous efforts of the principal investigator, Dr Joost Daemen (cardiologist at Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), over 35 participating centers and ECRI (sponsor of the trial), the patient enrollment has concluded. Following the tremendous efforts of the principal investigator,DrJoost Daemen (cardiologist at Thoraxcenter at theErasmus UniversityMedical Center,Rotterdam, The Netherlands ), over 35 participating...
Comunicato Precedente

next
Comunicato Successivo

next

Following the tremendous efforts of the principal investigator, Dr Joost Daemen (cardiologist at Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), over 35 participating centers and ECRI (sponsor of the trial), the patient enrollment has concluded.

"The FASTIII trial is aimed to establish the role of vFFR to coronary revascularization in patients with intermediate coronary artery lesions. An important milestone was reached Friday, May 31st, 2024, when the last patient was enrolled", said Joost DaemenPrincipal Investigator of the trial. "The next phase will consist of close follow-up of all patients who generously agreed to participate in the important trial. We hope to present our findings by the end of 2025".

Additionally,

"PMI is committed to providing clinicians and patients with long-term coronary data to inform their treatment decisions, " said René Guillaume, Managing Director at Pie Medical Imaging. "Our prior studies have shown diagnostic accuracy and reproducibility of vFFR calculation". FASTIII will establish its role in routine clinical practice.

The trial is funded by research grants from Pie Medical Imaging (Maastricht, The Netherlands) and Siemens Healthineers (Erlangen, Germany). The study is sponsored by ECRI (European Cardiovascular Research Institute, Rotterdam-the Netherlands). Cardialysis (Rotterdam, The Netherlands) is responsible for trial services including trial management and Core Laboratory activities.

Pie Medical Imaging announces enrollment completion of the FASTIII clinical trial

About Pie Medical Imaging

Pie Medical Imaging BV is a world leader in analysis and visualization of cardiovascular images. In Maastricht (The Netherlands), it hosts the global sales for the CAAS and 3mensio product lines.

PMI and 3mensio Medical Imaging part of the Esaote Group, leader in the biomedical equipment sector.  More information about PMI is available at www.piemedicalimaging.com 

Photo - https://mma.prnewswire.com/media/2438118/CAAS_vFFR.jpg
Logo -  https://mma.prnewswire.com/media/2438117/PMI_logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/pie-medical-imaging-announces-enrollment-completion-of-the-fastiii-clinical-trial-302172284.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;